Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

$RGBP -Positive Data - Pre Clinical - Advances Made Auto Immune Diseases - Two New Markets Unveiled (Rheumatoid Arthritis And Psoriasis) $18 Billion Worldwide

www.regenbiopharmainc.com

Regen BioPharma Discovers Two Possible New Markets Worth $18 + Billion (2018-2020)

Regen BioPharma Inc. (RGBP), (RGBPP) today announced completion of experiments demonstrating immunological effects of its novel NR2F6 small molecule modulators. These experiments were conducted in collaboration with Dr. Xiaojing Ma, Professor of Microbiology and Immunology at Weill Cornell Medical College.

The experiments revealed that administration of Regen's proprietary compounds RG-NA01, RG-NI01 and RG-NI02 prevented cells of the immune system from producing the inflammatory factors interleukin-2, interferon-gamma, tumor necrosis factor-alpha and, importantly, interleukin-17a. These factors are critically involved in the immune response found in autoimmune diseases such as rheumatoid arthritis and psoriasis. http://finance.yahoo.com/news/regen-biopharma-inc-receives-positive-121400084.html

Major Advances made in Auto Immune Diseases

The US treatment market for Rheumatoid Arthritis (NYSE:RA) is set to increase in value from $6.4 billion in 2013 to $9.3 billion by 2020, representing a Compound Annual Growth Rate (OTCPK:CAGR) of 5.5%, says business intelligence provider GBI Research - See more at: http://drug-dev.com/Main/Back-Issues/US-Rheumatoid-Arthritis-Treatment-Market-Value-to-900.aspx#sthash.iJLmb0it.dpuf

Psoriasis drug market will reach $8.9bn in 2018 predicts vision gain report

A new report by vision gain predicts the world psoriasis drug market will be worth $8.9bn in 2018. Those products, treating that indication, generated $6bn in 2012, according to Psoriasis Treatment: World Drug Market 2013-2023, published in September 2013. Vision gain is a business information provider based in London, UK.

Regen is making huge advancements in many different areas with Multiple "New Drugs"

HemaXelerate - FDA Cleared for Human Phase I & II Trials has had great results in treatment of aPlastic Anemia a rare blood disease, and realized a "New Market" worth $6 Billion for the purpose of treating "Bone Marrow Suppression due to Chemo Treatments.

dCellVax- Awaits FDA clearance for Human Trials, when cleared they will commence Trails with 10 Females who have Breast Cancer. Regen just answered comments which could have been the final set of comments/answers, including Updated Pre Clinical Data.

tCellVax - Regen has submitted the application focused on using a "Novel Method" to unleash the body's innate ability to "Kill" Cancer using siRNA.

As You Can See $RGBP$ Has Made Many Great an Advancement in Just the Past Year Evolving from an R & D to a Clinical Stage Company

They have also developed several "Partnerships" this year. NIH (NCATS), Eli Lily & Co., Pan Am Cancer Research and Treatment Center, and it would seem the newest being todays feature above-Weill Cornell Medical College.

Some Very Exciting Times @ Regen BioPharma, Inc.

Barchart Technical Opinion

More

RESULTS OF 13 POPULAR ANALYTICS

Overall Average:

80%

Strong Buy


Support & Resistance

More

2nd Resistance Point

0.1574

1st Resistance Point

0.1502

Last Price

0.1426

1st Support Level

0.1354

2nd Support Level

0.1278

We still believe $RGBP-$RGBPP are Both LONG PLAYS with a Huge Future-Possibly a Buy Out Target. Short Term Gain Potential is Evident as it has Run Many Times I the Past-Most Recently Popping from $0.08 to $0.15 between 8/8/16 and now.

If you have any questions, please contact me-If you have any connections to "Friendly" Financing please let me know.

Thanking you in advance for your consistent support

Robert E. Kreh

Principal

Small Cap Solutions, LLC

(443) 567-2609

robkreh@smallcapsolutions.com

(OTCPK:RGBP)

Disclaimer: You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Regen BioPharma, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at www.otcmarkets.com. Small Cap Solutions, LLC has received ($1000.00) cash from Value Quest, Inc. for investor relations services rendered for Regen BioPharma, Inc. . Additional inquiries are available by email to robkreh@smallcapsolutions.com or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclaimer: All Micro/Small Cap Company(ies) profile(s) are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein.

Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at yahoofinance.com and/or otcmarkets.com Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.

Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker(s)/Broker Dealer(s) with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to robkreh@smallcapsolutions.com or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.